Delaware
|
001-34600
|
26-2593535
|
||
(State or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
£
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
£
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
£
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
£
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Exhibit No.
|
Description
|
|
Press Release dated March 4, 2014.
|
Date: March 6, 2014
|
Oxygen Biotherapeutics, Inc.
|
|
By: /s/ Michael B. Jebsen
|
||
Michael B. Jebsen
|
||
|
Chief Financial Officer
|
Exhibit No.
|
Description
|
|
Press Release dated March 4, 2014.
|
U`"T5%
M;W,%W`L]M-'-"WW9(V#*>W!%2T`%%%%`!6'JGB_0]&NC:WM^J3@`LBHSE<^N
MT'%;;9"''7'%?-%R\TES*]P7,[.3(7^\6SSGWS7H8#!QQ,GS.R1YV8XV6&C'
ME6K/HW3]2L]5M%NK&X2>%OXE['T(Z@^QJW7E'PEDN?[2U",$FU\E6?T#Y^7]
M-WY5ZO7/BJ"H5733N=&$KNO151JP5S7CK6Y=#\-236S%;B9Q!&X_@)!)/Y`X
M]\5TM<=\3+":]\)F2%=WV699G`&3MP5)_#=GZ`USG2:_A?18]$T."`)BXD42
M7#GEGD(R:P::9H%'EMQ(I(*L<8!R"!GKVS6
M-;:#JMO;Z26-K)+8^:YB\Q@K2,N-Y;!R=Q<]!C?QTR2^TN:TTW2],M9_.OFO
M//>=QSNRSO*1Z!F''N!GFG*-.3M?^E_PUR8SJ16W]/\`X>QI3ZO;7